That’s what they’re going to do? A 1:500 split? Read the 8-k, it’s just an open ended figure so they’re not held accountable to their real figure if and when it ever comes out in 2019. The investor and owners will have the last say in this game of poker. This is not an uncommon thing in the biopharma industry. Everyone should buck up, shut up, and vote accordingly.
News 
Market Data 
Discover 
